Thank you, Mr. Chair.
My question is for Dr. Grandvaux. I'll try to be brief so she has time to answer.
We're being told that what we are doing now is time management, because there isn't a vaccine or an antiviral drug yet. We're starting to see serological testing, and we're realizing that tracing is important and screening alone isn't enough. Dr. Nemer said earlier that we've been playing catch-up.
Dr. Grandvaux, during one of your talks, you said that we were fighting an unknown enemy, and you said earlier that we had abandoned fundamental research.
At this point, what are the main lessons we should be drawing from this situation so we don't make the same mistakes?